Story at-a-glance
- One of the primary vehicles for kickbacks and fraud seems to be foundations associated with federal agencies. The reason they’re so frequently used for questionable transactions is because foundations are private entities and not subject to Freedom of Information Act requests and other open records laws
- The board of directors of the Foundation for the National Institutes of Health (FNIH) is heavily populated with Big Pharma players. This raises serious questions about conflicts of interest, as the foundation oversees the distribution of hundreds of millions of dollars — unregulated funds that typically go right back into the coffers of the drug industry
- This conflict of interest also, at least in part, helps explain the actions of Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases (NIAID) and now-retired director of the NIH, Dr. Francis Collins. Both have gone out of their way to protect the makers of COVID shots and dismiss evidence that SARS-CoV-2 was created in and escaped from a lab
- Dr. Julie Gerberding became the FNIH CEO March 1, 2022. She was formerly director of the U.S. Centers for Disease Control and Prevention. After leaving the CDC, she became the executive vice president of strategic communications at Merck
- The FNIH’s board of directors includes seven current or former drug company executives, the FDA, the Sackler family (notorious for its creation of a deadly opioid epidemic), Johns Hopkins (co-sponsor of Event 201, which “predicted” COVID-19 and the subsequent destruction of human rights), and two major investment bankers, Goldman Sachs and BlackRock
Continue reading “Massive Conflicts of Interest at the NIH”
